Soleno Therapeutics (NASDAQ:SLNO) announced the issuance of a new US patent from the related to the use of pharmaceutical formulations of diazoxide and its salts.
As quoted in the press release:
Prader-Willi syndrome (PWS) is a rare and complex genetic neurobehavioral/metabolic disorder affecting appetite, growth, metabolism, cognitive function, and behavior. SMS is a rare disorder with a distinct genetic basis, but a natural history similar to that of PWS.
“This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”